CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

BELLUS Health (BLU) stock jumps 76% after Phase 2 trial results

By Kevin Donovan

20:57, 13 December 2021

Illustration of refractory chronic cough
BLU-5937 medication reduced 24-hour cough frequency by 34% – Photo: BELLUS Health

BELLUS Health stock traded as high as 76% higher Monday, after the biopharmaceutical announced positive results of the Phase 2 test for its refractory chronic cough (RCC) medication and said it expects to begin Phase 3 trials next year.Phase-2B SOOTH trial

Laval, Quebec, Canada-based BELLUS Health said the topline results for its BLU-5937 medication reduced 24-hour cough frequency by 34% on a placebo-adjusted basis among Phase 2b SOOTHE trial subjects within one month of beginning treatment. Additionally, subjects reported low rates of taste-related adverse effects from taking BLU-5937, the company reported.

BELLUS Health stock jumped over 76% after the pre-market open announcement before moving slightly lower to $8.45 per share, up 51.2%. Over 100 million BELLUS Health shares traded hands as of 15:00 ET (UTC-5), according to data maintained by Nasdaq. Belus Health trades over the Nasdaq exchange under the ticker “BLU”.

Illustration of coughIllustration of cough – Photo: BELLUS Health

The next stage

The Phase-2b SOOTHE among 249 subjects each with a baseline cough frequency greater than 25 per hour, experienced a greater than 34% cough reduction by day 28 of the trial. Adverse taste-related side effects were reported in 4.80% to 6.50% of subjects, depending on the dosage.

“We are extremely pleased with the compelling topline results from the Phase 2b SOOTHE trial which highlight BLU-5937’s best-in-class potential for the treatment of refractory chronic cough,” said BELLUS Health CEO Roberto Bellini in a press release. “RCC is a prevalent and growing condition that significantly impacts the quality of life of an estimated (nine) million patients in the United States and (nine) million patients in Europe.”

BELLUS now plans to end its Phase2 testing and plans to petition the US Food & Drug Administration (FDA) next year to begin final Stage 3 testing in the second-half of 2022. 


16.93 Price
+9.800% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 0.13


454.78 Price
-2.980% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 0.19


142.67 Price
+6.040% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 0.20


7.07 Price
+2.330% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 0.03

Between 20% and 46% of patients seeking treatment for Hypersensitivity syndrome are estimated to suffer from RCC, which is defined as a persistent, dry cough lasting at least eight weeks, according to the Mayo Clinic’s Cough Clinic in Rochester Minnesota.

BELLUS estimates nine million suffer from RCC in the US alone, according to a BELLUS investor presentation, calling the market a “significant unmet need.”

Merck also manufactures a P2X3 antagonist treatment, MK-7264, which is pending FDA approval. Merck, however, has reported potential side effects of MK-7264 may include the loss of taste in test subjects.

Public offering of shares

The company also launched a $175m public offering of common shares in Canada and the US. BELLUS Health plans to use the proceeds primarily to fund research and development activities, general and administrative expenses, working capital needs and other general corporate purposes.

Jefferies, Evercore ISI and RBC Capital Markets are acting as joint book–running managers

Read more: Merck moves higher on FDA petition for new oral Covid-19 drug

Rate this article

The difference between trading assets and CFDs
The main difference between CFD trading and trading assets, such as commodities and stocks, is that you don’t own the underlying asset when you trade on a CFD.
You can still benefit if the market moves in your favour, or make a loss if it moves against you. However, with traditional trading you enter a contract to exchange the legal ownership of the individual shares or the commodities for money, and you own this until you sell it again.
CFDs are leveraged products, which means that you only need to deposit a percentage of the full value of the CFD trade in order to open a position. But with traditional trading, you buy the assets for the full amount. In the UK, there is no stamp duty on CFD trading, but there is when you buy stocks, for example.
CFDs attract overnight costs to hold the trades (unless you use 1-1 leverage), which makes them more suited to short-term trading opportunities. Stocks and commodities are more normally bought and held for longer. You might also pay a broker commission or fees when buying and selling assets direct and you’d need somewhere to store them safely.
Capital Com is an execution-only service provider. The material provided on this website is for information purposes only and should not be understood as an investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page then you do so entirely on your own risk.

Still looking for a broker you can trust?

Join the 570.000+ traders worldwide that chose to trade with

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading